Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186172 | 1.00 | NR1H2 (0.53) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL30426904 | 1.00 | NR1H2 (0.53) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL30426972 | 1.00 | NR1H2 (0.53) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL20139589 | 0.90 | NR1H2 (0.59) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL24794734 | 0.88 | MAP4K4 (0.51) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL29709724 | 0.88 | MAP4K4 (0.51) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL24794736 | 0.88 | MAP4K4 (0.51) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL29709794 | 0.88 | MAP4K4 (0.51) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL17385218 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 | |
| SCHEMBL17375389 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3MAP4K4HDAC1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | NR1H2 4618/4885NR1H3 4524/4885MAP4K4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.